DORAVIPEP evaluated the use of co-formulated DOR/3TC/TDF as nonoccupational post-exposure prophylaxis (PEP).  This was a single-center, open-label, single-arm trial which included 399 non-pregnant adults (91% male and 84% MSM) seeking emergency department care after consensual, potential exposure to HIV between September 2019 and March 2022.  Participants received a complete 28-day prescription, with the first dose initiated immediately on day 0.  34.6% reported prior PEP use and 6% had initiated pre-exposure prophylaxis (PrEP) prior to the study.  During the follow-up period, 29% discontinued PEP early; median time reported for PEP duration was 8 days.  The most common reason for non-completion was loss to follow-up, followed by intolerance and adverse events.  In multivariable analysis, PEP non-completion was associated with younger age; among individuals who attended at least 1 post-enrollment visit, both younger age and any AE emergence was associated with PEP non-completion.  The most common AE types were gastrointestinal (35%), neurological (21%), and musculoskeletal (9%).  No clinically significant laboratory value changes were observed, and laboratory abnormalities were not the reason for PEP non-completion in any participant.  Self-reported adherence in assessed participants was 336/350 (96%) and 281/285 (99%) at day 7 and week 4, respectively.  No cases of seroconversion were identified.